KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$6.72 USD
+0.27 (4.19%)
Updated May 31, 2024 04:00 PM ET
After-Market: $6.73 +0.01 (0.15%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth C Momentum F VGM
Brokerage Reports
0 items in cart
KALA BIO, Inc. [KALA]
Reports for Purchase
Showing records 61 - 80 ( 365 total )
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Shifting Focus to Value-Driving Assets; Assuming Coverage at OUTPERFORM & $6 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Eyes Wide Open: Setting Our Sights on a New Frontier in Ocular Disease
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Shifting Focus to Value-Driving Assets; Assuming Coverage at OUTPERFORM & $6 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS EYSUVIS?
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Q3: EYSUVIS & INVELTYS Plagued by Pandemic Headwinds; Pipeline Expands
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Orphan Drug Acquired; 3Q21 Results; Reiterate Buy; Modulating PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Recently Approved Nasal Spray Not An Option for Acute Dry Eye; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L